Liu Su-Tong, Su Kai-Qi, Zhang Li-Hui, Liu Ming-Hao, Zhao Wen-Xia
Henan University of Chinese Medicine.
Department of Gastroenterology, The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, Henan, PR China.
Medicine (Baltimore). 2020 Aug 7;99(32):e21568. doi: 10.1097/MD.0000000000021568.
Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in Western countries, and strongly associated with type 2 diabetes mellitus (T2DM). Several studies have shown that hypoglycemic agents are effective for NAFLD combined with T2DM. However, there is still controversy over which hypoglycemic agent is the best for NAFLD combined with T2DM patients.
To systematically evaluate the efficacy and safety of hypoglycemic agents in NAFLD combined with T2DM patients.
A comprehensive electronic search will be conducted by searching Web of Science, PubMed, EMBASE, Cochrane Central Register of Controlled Trials, Clinical Trials and Chinese Biomedical Medicine. All randomized controlled trials of hypoglycemic agents interventions for NAFLD combined with T2DM will be identified. Two reviewers independently screened and evaluated each included study and extracted the outcome indexes. ADDIS 1.16.8 software will be used for the network meta-analysis and STATA 14 software will be used for drawing network evidence plots and funnel plots.
This network meta-analysis will provide stronger evidence for the efficacy and safety of hypoglycemic agents in the treatment of NAFLD combined with T2DM, and provide a reference for clinical application.
INPLASY202070016.
非酒精性脂肪性肝病（NAFLD）是西方国家慢性肝病的最常见病因，且与2型糖尿病（T2DM）密切相关。多项研究表明，降糖药物对合并T2DM的NAFLD有效。然而，对于合并T2DM的NAFLD患者，哪种降糖药物最佳仍存在争议。
系统评价降糖药物对合并T2DM的NAFLD患者的疗效和安全性。
通过检索Web of Science、PubMed、EMBASE、Cochrane对照试验中央注册库、临床试验和中国生物医学数据库进行全面的电子检索。将识别所有关于降糖药物干预合并T2DM的NAFLD的随机对照试验。两名评价员独立筛选和评估每项纳入研究，并提取结局指标。将使用ADDIS 1.16.8软件进行网络荟萃分析，使用STATA 14软件绘制网络证据图和漏斗图。
该网络荟萃分析将为降糖药物治疗合并T2DM的NAFLD的疗效和安全性提供更有力的证据，并为临床应用提供参考。
INPLASY202070016。
